Back to Treatments

Treatment

Trastuzumab (for HER2+ Adenocarcinoma)

1
Conditions
15
Trials
3,000
Participants
55%
Average Safety

Condition Evidence

Esophageal cancer

15 trials · 3,000 participants

60% effectiveness · 55% safety
Trastuzumab (for HER2+ Adenocarcinoma) | DFDA